LUPIN | BH.IMMUN&BIO | LUPIN/ BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 40.7 | -8.0 | - | View Chart |
P/BV | x | 6.0 | 1.6 | 379.9% | View Chart |
Dividend Yield | % | 0.2 | 0.0 | - |
LUPIN BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LUPIN Mar-23 |
BH.IMMUN&BIO Mar-23 |
LUPIN/ BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 799 | 52 | 1,542.3% | |
Low | Rs | 583 | 21 | 2,844.1% | |
Sales per share (Unadj.) | Rs | 365.8 | 10.3 | 3,540.5% | |
Earnings per share (Unadj.) | Rs | 9.8 | -3.9 | -255.4% | |
Cash flow per share (Unadj.) | Rs | 29.2 | -3.8 | -766.9% | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 270.7 | 20.4 | 1,325.0% | |
Shares outstanding (eoy) | m | 454.98 | 43.18 | 1,053.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.9 | 3.5 | 54.0% | |
Avg P/E ratio | x | 70.2 | -9.4 | -748.5% | |
P/CF ratio (eoy) | x | 23.7 | -9.5 | -249.2% | |
Price / Book Value ratio | x | 2.6 | 1.8 | 144.3% | |
Dividend payout | % | 40.7 | 0 | - | |
Avg Mkt Cap | Rs m | 314,381 | 1,561 | 20,140.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 30,872 | 151 | 20,384.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,417 | 446 | 37,305.6% | |
Other income | Rs m | 1,509 | 11 | 14,236.8% | |
Total revenues | Rs m | 167,926 | 457 | 36,770.2% | |
Gross profit | Rs m | 17,206 | -161 | -10,707.4% | |
Depreciation | Rs m | 8,807 | 2 | 440,345.0% | |
Interest | Rs m | 2,743 | 71 | 3,885.3% | |
Profit before tax | Rs m | 7,165 | -223 | -3,217.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,688 | -56 | -4,775.3% | |
Profit after tax | Rs m | 4,477 | -166 | -2,690.6% | |
Gross profit margin | % | 10.3 | -36.0 | -28.7% | |
Effective tax rate | % | 37.5 | 25.3 | 148.4% | |
Net profit margin | % | 2.7 | -37.3 | -7.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 124,513 | 358 | 34,777.3% | |
Current liabilities | Rs m | 92,654 | 940 | 9,852.4% | |
Net working cap to sales | % | 19.1 | -130.6 | -14.7% | |
Current ratio | x | 1.3 | 0.4 | 353.0% | |
Inventory Days | Days | 26 | 85 | 30.7% | |
Debtors Days | Days | 98 | 1,135 | 8.7% | |
Net fixed assets | Rs m | 103,490 | 1,262 | 8,201.2% | |
Share capital | Rs m | 910 | 432 | 210.7% | |
"Free" reserves | Rs m | 122,246 | 450 | 27,145.2% | |
Net worth | Rs m | 123,156 | 882 | 13,961.0% | |
Long term debt | Rs m | 275 | 0 | - | |
Total assets | Rs m | 228,003 | 1,620 | 14,074.9% | |
Interest coverage | x | 3.6 | -2.2 | -167.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 0.3 | 265.0% | |
Return on assets | % | 3.2 | -5.9 | -53.5% | |
Return on equity | % | 3.6 | -18.9 | -19.3% | |
Return on capital | % | 8.0 | -17.2 | -46.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 14.5 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 65 | 0.0% | |
Fx inflow | Rs m | 48,057 | 0 | - | |
Fx outflow | Rs m | 21,752 | 65 | 33,713.1% | |
Net fx | Rs m | 26,306 | -65 | -40,771.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,972 | 109 | 17,418.7% | |
From Investments | Rs m | -12,868 | 5 | -278,521.6% | |
From Financial Activity | Rs m | -3,373 | -147 | 2,292.3% | |
Net Cashflow | Rs m | 2,732 | -34 | -8,138.8% |
Indian Promoters | % | 46.7 | 59.3 | 78.9% | |
Foreign collaborators | % | 0.3 | 0.0 | - | |
Indian inst/Mut Fund | % | 46.1 | 0.0 | - | |
FIIs | % | 18.3 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 53.0 | 40.8 | 130.0% | |
Shareholders | 280,248 | 35,313 | 793.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare LUPIN With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Lupin | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 1.68% | -2.69% | 0.45% |
1-Month | 0.21% | 6.17% | 2.55% |
1-Year | 128.16% | 31.70% | 56.14% |
3-Year CAGR | 14.99% | -9.09% | 15.22% |
5-Year CAGR | 13.23% | 32.05% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Lupin share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of Lupin hold a 47.0% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Lupin and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, Lupin paid a dividend of Rs 4.0 per share. This amounted to a Dividend Payout ratio of 40.7%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Lupin, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.